GET DAILY SIGNALSWhy Is Caris Life Sciences (CAI) Stock Down -22.07% Today?
Key Takeaways
- CAI shares tumbled roughly 22% on Wednesday, extending a steep post-earnings decline after the company's third-quarter report.
- The primary catalyst was a beat-and-raise quarter that nonetheless exposed shrinking margins, rising expenses, and a swing to negative free cash flow.
- Profitability fell year over year, with net income dropping about 37% even as revenue climbed 27%.
- The sell-off also reflected profit-taking after a sharp run-up that left the stock trading at a premium valuation.
- Analysts largely defended the name, with some raising price targets while framing the drop as an overreaction.
- Traders are now watching fourth-quarter volume guidance, upcoming product launches, and whether the stock can stabilize near technical support.
- For deeper data on Price Targets, Earnings, and Forecast, explore the dedicated analysis pages for this ticker.
- To see which strategies are performing best right now, visit the curated Trending AI Robots section.
Opening Summary
Caris Life Sciences, Inc. (CAI), an artificial intelligence–driven "TechBio" company that provides molecular profiling and precision oncology diagnostics, saw its shares plunge in Wednesday's session. The stock fell from a prior close of $33.22 to an intraday low around $25.89, a decline of roughly 22.07%. The move marks a sharp extension of the selling that began in after-hours trading Tuesday, when investors reacted to the company's third-quarter 2026 results. Despite revenue that beat expectations and a raised full-year outlook, the market focused on compressed margins, higher operating costs, and a turn to negative cash flow, triggering a decisive downward re-rating.
Q3 Earnings: A Beat-and-Raise That Still Disappointed
The headline numbers initially looked strong. Caris reported third-quarter revenue of $275.4 million, up 27% year over year and above analyst estimates, driven by molecular profiling services and a 21% jump in clinical case volume to roughly 61,500 cases. Management also raised its full-year 2026 revenue guidance to a range of $1.04 billion to $1.05 billion, implying 28% to 29% growth.
Yet the profit picture told a different story. Net income attributable to common shareholders fell to $15.3 million, or $0.05 per share, from $24.3 million, or $0.08 per share, in the prior-year quarter. Adjusted EBITDA also declined to $44.4 million from $51.2 million a year earlier. The combination of strong top-line growth with shrinking bottom-line profitability is a classic setup for post-earnings volatility, and it is the central reason the market sold the report.
Margin Compression and Cash-Flow Concerns
Beneath the revenue beat, investors homed in on deteriorating profitability. Gross margin slipped to 66% from 68% a year earlier, while operating expenses surged 42% to $163.0 million, reflecting aggressive investment in sales, marketing, and research and development ahead of multiple new product launches.
Cash generation was the most troubling metric. Operating cash flow swung to an outflow of $22.2 million from an inflow of $62.4 million a year earlier, and free cash flow turned negative at -$39.7 million versus +$55.3 million in the prior-year period. For a company that had been moving toward sustained profitability, the return to negative free cash flow gave bears a concrete reason to reassess the stock's premium valuation.
Valuation and Profit-Taking After a Steep Run
The magnitude of the decline was amplified by how far the stock had already climbed. Shares had gained roughly 75% over the prior six months, leaving the equity trading above many analysts' fair-value estimates and in technically overbought territory. With that setup in place, the earnings report became a trigger for broad-based profit-taking. Fourth-quarter volume guidance—which implied a meaningful sequential acceleration—added another layer of skepticism, as some investors questioned whether there was limited room for upside surprises.
Market Context and Trading Activity
Trading was heavy as the post-earnings re-rating unfolded, with selling pressure extending from Tuesday's after-hours session into Wednesday's regular session. The decline was largely company-specific rather than a reflection of broad market weakness, given that the move was driven by Caris's own fundamental and valuation considerations. The stock broke decisively below its recent consolidation range in the low-to-mid $30s, and technical signals that had flashed overbought readings in late October deteriorated rapidly as momentum shifted to the downside.
Notably, Wall Street's initial response was more constructive than the market's. Several analysts maintained bullish ratings, with some raising price targets on the strength of Caris's pipeline and product launches, while characterizing the sell-off as an overreaction to a quarter in which the company beat expectations and raised guidance.
What Comes Next for CAI
Looking ahead, investors will focus on whether Caris can deliver on its fourth-quarter volume targets and demonstrate a path back to positive free cash flow. Key watch items include the planned launch of the Caris Confirm minimal residual disease assay before year-end, early uptake of the Caris Assure therapy-response-monitoring offering, and reimbursement developments tied to the 2027 Clinical Lab Fee Schedule. The company's substantial cash position of roughly $767 million provides a cushion as it invests through this launch cycle.
Risks remain, however. Continued margin pressure, slower-than-expected pharma research revenue, and any shortfall in the guided volume acceleration could renew selling pressure. Conversely, confirmation that the elevated spending is translating into durable growth could help the stock stabilize after this sharp reset.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading bots that are performing well under current market conditions. While Tickeron offers hundreds of bots covering thousands of tickers, only the strongest performers are featured in this section, with strategies that vary by approach, timeframe, performance metrics, and traded symbols. Exploring the page can help traders identify automated strategies aligned with today's fast-moving, earnings-heavy environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for CAI turns positive, indicating new upward trend
CAI saw its Momentum Indicator move above the 0 level on October 15, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator turned positive. In 21 of the 27 cases, the stock moved higher in the following days. The odds of a move higher are at 78%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +3.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where CAI advanced for three days, in 46 of 67 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
Bearish Trend Analysis
The 10-day RSI Indicator for CAI moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 7 similar instances where the indicator moved out of overbought territory. In 5 of the 7 cases, the stock moved lower in the following days. This puts the odds of a move lower at 71%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 15 of 17 cases where CAI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for CAI turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 10 similar instances when the indicator turned negative. In 10 of the 10 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CAI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
CAI broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. CAI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.865) is normal, around the industry mean (2.904). P/E Ratio (3.468) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (9.059). Dividend Yield (0.021) settles around the average of (128.314) among similar stocks. P/S Ratio (8.084) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CAI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in the business of leasing international intermodal marine cargo containers
Industry Biotechnology
Advertisement